渤海证券研究所晨会纪要（2025.09.08）-20250908

Macro and Strategy Research - The U.S. economy is experiencing a shift in the balance of risks between inflation and employment, with a potential monetary policy shift expected in September. The focus is on August's non-farm payroll and inflation data, as well as adjustments to the annual non-farm benchmark [2] - In Europe, economic expectations are improving, and stable inflation allows the European Central Bank (ECB) to maintain current policy rates. ECB President Lagarde indicated that trade negotiations are not posing significant threats to monetary policy [2] Domestic Economy - Domestic economic growth slowed in July due to extreme weather and policy expectations, characterized by strong external demand and weak internal demand. Future external demand growth is expected to be supported by a weakening U.S. demand and a reshaped long-term trade landscape [3] - The domestic policy environment emphasizes stabilizing market expectations and strengthening the domestic circulation, with structural monetary policies focusing on inclusive finance and technological innovation [3][4] Fixed Income Research - In August, the central bank injected a net liquidity of 386.5 billion yuan, maintaining low funding prices. The issuance of interest rate bonds decreased to 3 trillion yuan, with net financing increasing to 1.7 trillion yuan [6][7] - The bond market is expected to face pressure from external demand uncertainties and "anti-involution" measures, with a focus on the stability of the funding environment in September [8] Industry Research - The medical insurance payment management method was introduced in August, and the 11th batch of centralized procurement is progressing. The medical care CPI in July was 100.5, with a year-on-year increase of 0.5% [9][10] - The pharmaceutical manufacturing industry reported a cumulative revenue of 1,401.07 billion yuan from January to July, a year-on-year decrease of 1.7%, while cumulative profits fell by 2.6% [10] - The upcoming World Lung Cancer Conference (WCLC) is expected to provide opportunities for innovation in the pharmaceutical and medical device sectors, with a focus on companies benefiting from optimized procurement rules and the recovery of domestic demand [10]